Navigation Links
Infectious Disease Specialist, Brad Spellberg, M.D., Joins Synthetic Biologics' Scientific Advisory Board
Date:2/26/2013

ROCKVILLE, Md., Feb. 26, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that Brad Spellberg , M.D., joined the Company's Scientific Advisory Board. Dr. Spellberg is an infectious disease specialist whose NIH-funded laboratory studies highly drug-resistant infections in an effort to develop vaccines and immune therapies to prevent and treat them. He has also worked closely with the Infectious Diseases Society of America (IDSA) to focus attention on the rising public health crisis caused by increasing antibiotic resistance and decreasing new antibiotic development.

Dr. Spellberg is an Associate Professor of Medicine, David Geffen School of Medicine in the Division of General Internal Medicine at Harbor-UCLA Medical Center, and Associate Program Director for Internal Medicine Residency Training Program, Harbor-UCLA Medical Center and LA BioMed. His research regarding new drug development for the prevention and treatment of infectious diseases became the foundation for the IDSA's white paper, "Bad Bugs, No Drugs," and has been cited extensively in medical publications and on Capitol Hill. He is a Fellow in the IDSA and has served as Co-Chair of the IDSA's Antimicrobial Availability Task Force (AATF). As a member of the AATF, he has first-authored numerous IDSA position papers and review articles relating to public policy of antibiotic resistance and antibiotic development. Dr. Spellberg is also the author of Rising Plague: The Global Threat from Deadly Bacteria and Our Dwindling Arsenal to Fight Them, which he wrote to inform and educate the public about the crisis in antibiotic resistant infections and lack of antibiotic development.

"As we expand our infectious disease pipeline, we are very pleased to welcome Dr. Spellberg to our Scientific Advisory
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Infectious Immunology Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
2. Synthetic Biologics to Acquire Clinical-Stage C. difficile Infectious Disease Program
3. Frost & Sullivan: Asia Pacific Infectious Disease Diagnostics Market Grows as Economies Boom and Countries Become Image Conscious
4. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
5. Infectious Disease Prevalence and New Strains Appearing Each Year Makes a Watertight Case for Clinical Laboratory Testing, Finds Frost & Sullivan
6. Soligenix Announces Collaboration with Infectious Disease Research Institute to Develop Thermostabilized Biodefense Vaccines Utilizing Novel Adjuvants
7. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
8. US Lab Deployed to Boost Mexicos Response to Outbreaks of Infectious Disease
9. India In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
10. Modeling Alzheimers disease using iPSCs
11. GUARDaHEART Foundation Hosts Love Your Heart Day Event in Celebration of Heart Disease Awareness Month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, Inc. ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a primary commercial focus on ... been granted a Type C meeting with the U.S. ... will be held in February 2015.  During this meeting ...
(Date:12/15/2014)... , Dec. 15, 2014 Organovo ... biology company focused on delivering breakthrough 3D bioprinting ... industry and collaborators of its exVive3D TM ... widely available in full commercial release on November ... field, resulting in several awards for innovation. ...
(Date:12/13/2014)... MaRS and Virgin Unite Canada, the non-profit foundation of the ... support Canadian entrepreneurs tackling social and environmental challenges. Today, Sir ... MaRS Centre to announce the new partnership, which includes the ... has $1 million in seed capital provided by Virgin Unite ... Innovation Foundation, founded by Alison Lawton . ...
(Date:12/13/2014)... According to population studies: “North Carolina ... and 2030." If a population explosion like that actually ... state in the country. , To that end, North ... of North Carolina Forum on December 16th to ask ... necessary infrastructure in place? Enough clean water? And will ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3North Carolina Chamber of Commerce: Asking Questions & Gathering Answers with a Futurist 2
... as Lead Epidemiologist, RALEIGH, N.C., Oct. 27 ... today the appointment of Dr.,Jerome Wilson as Senior ... Epidemiologist, Dr. Wilson is responsible for providing consulting,services ... PRA provides extensive Phase IV Post-Marketing services to,pharmaceutical ...
... October 27 Stallergenes has,just obtained authorization (IND(1)) from ... in the United States with Oralair(R) Grasses in,the treatment ... The aim of the study, which will be conducted ... to confirm the efficacy and good,tolerance of the product ...
... Beckman,Coulter, Inc. (NYSE: BEC ), a ... simplify, automate, and innovate complex biomedical,testing, announced ... and chief executive officer, will present at ... 4, 2008 at 1:20 p.m.,(ET)., (Logo: ...
Cached Biology Technology:Jerome Wilson Joins PRA International's Late Phase Service Group 2Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009 2Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009 3
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... Robert Linhardt has spent years stitching together minuscule carbohydrates ... commonly used and controversial blood thinner heparin. At the national ... Linhardt announced that his research team may have accomplished this ... is the largest dose of heparin ever created in the ...
... date for bipolar disorder has implicated machinery involved in the ... in part by the National Institute of Mental Health, part ... the disorder and variation in two genes that make components ... and out of cells, including neurons. "A neuron,s ...
... CHAMPAIGN, Ill. Understanding the form and function ... becoming faster and easier, thanks to the work ... combining custom-built spectrometers, novel probe designs and faster ... professor Chad Rienstra has developed unique capabilities for ...
Cached Biology News:Researchers create safer alternative to heparin 2Largest study of its kind implicates gene abnormalities in bipolar disorder 2Improved technique determines structure in membrane proteins 2
... mobility shift assay (EMSA) is a powerful ... to as gel shift or gel retardation, ... that when subjected to electrophoresis, free DNA ... The Pierce LightShift Chemiluminescent EMSA Kit is ...
... The Cell Lab Quantas unique ... provides unsurpassed population resolution capabilities and ... has multiple excitation wavelengths, including UV, ... variety of multi-color applications typically only ...
... Kit delivers a novel procedure for the ... of whole genome DNA from small samples. ... a quick and highly reproducible amplification and ... of a REPLI-g Mini Kit module (QIAGEN) ...
... be superior to transfection in some applications. ... PULSin you can study lethal proteins and ... proteins in cells. Likewise, delivery of blocking ... RNA interference experiments. ,With PULSin you ...
Biology Products: